GlassScriptPhysician profile
Paul Orton
NPI 1679624266
$5,937.20
in general payments reported to CMS, 2019-2025
28 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $297 · 2021: $226 · 2022: $813 · 2023: $1,575 · 2024: $793 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.24 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,311.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $498.61 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $496.82 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $464.95 | 2022-2025 | Opzelura |
| Pfizer INC. | $425.16 | 2020-2025 | |
| Janssen Biotech, INC. | $353.42 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $303.96 | 2019-2025 | |
| Lilly USA, LLC | $290.70 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $287.34 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $281.50 | 2019-2025 | Odomzo, Blu-U |
| Almirall LLC | $246.44 | 2019-2025 | Seysara |
| Novartis Pharmaceuticals Corporation | $195.46 | 2022-2024 | |
| Ucb, INC. | $158.93 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $97.87 | 2023 | Sotyktu |
| Merz North America, INC. | $76.29 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $60.19 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.04 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $44.41 | 2019 | |
| Kyowa Kirin, INC. | $41.51 | 2025 | |
| Arcutis Biotherapeutics, INC. | $40.81 | 2023-2024 | Zoryve |
| Aclaris Therapeutics, INC. | $39.52 | 2019 | |
| Dermira, INC. | $38.99 | 2020 | |
| Dermavant Sciences, INC. | $35.70 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $24.45 | 2019 | |
| Journey Medical Corporation | $19.35 | 2020 | |
| Amgen INC. | $19.32 | 2025 | Otezla |
| Botanix Sb INC | $18.63 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $15.44 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Orton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.